BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tertomotide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tertomotide\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05303701-729@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tertomotide: Phase 3 readout est. (NCT05303701)
DESCRIPTION:Tertomotide\, phase 3\, Alzheimer's Disease.\nStudy: GV1001 Sub
 cutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)\
 nEstimated primary completion: January 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tertomotide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05303701
URL:https://assetmemo.bio/drug/tertomotide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
